Tuesday, October, 22, 2013 - New York City
Alexandria Center™ for Life Science

Preliminary Program

-7:45 - 8:30:  Introduction: 
Chair:  Dr. P.Roy Vagelos, Chairman of Regeneron Pharmaceuticals and retired Chairman and Chief Executive Officer at Merck & Co., Inc.
Keynote Speaker:  Bert Vogelstein, Johns Hopkins School of Medicine.
Joel Marcus, Chairman A.R.E.
Kris Joshi PhD, Global Vice President, Oracle Health Sciences

-8:30 - 9:35:  New Mechanisms for Industry-Academia Interactions: Successes and Obstacles
Chair:  Dr. Michael Rosenblatt, Executive Vice-President and Chief Medical Officer, Merck
Dr. Christopher Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health
Dr. Michael S. Brown, The W.A. (Monty) Moncrief Distinguished Chair in Cholesterol and Arteriosclerosis Research, Regental Professor, and Paul J. Thomas Chair in Medicine, University of Texas Southwestern Medical Center
Dr. Robert M Califf, Vice Chancellor for Clinical and Translational Medicine, Director of the Duke Translational Medicine Institute (DTMI), and Professor of Medicine in the Division of Cardiology, Duke University
Dr. John Thomas Potts Jr., Distinguished Jackson Professor of Clinical Medicine, Massachusetts General Hospital and Harvard Medical School

- 9:35 - 10:40:  Improving efficiency in drug development: 
Chair:  Dr. Mikael Dolsten, President Worldwide Research and Development, Pfizer,Inc.
Dr. Jeff Leiden, Chairman, President and CEO, Vertex
Dr. Jan Lundberg, Executive Vice President, Science and Technology and President, Lilly Research Labs, Lilly & Co.
Dr. Elliott Sigal, Former Executive Vice President, Chief Scientific Officer and President, R&D,  BMS.

- 10:40 - 11:00:  Coffee Break

- 11:00 - 12:05:  Personalized medicine, Effect on drug R&D
Chair:  Pr. Joseph Goldstein, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center at Dallas
Dr. David Altshuler, Massachusetts General Hospital and Broad Institute    
Dr. Richard Lifton, Yale University School of Medicine
Dr. Jonathan  Sheldon, Global Senior Director of Translational Medicine, Oracle Health Sciences.
Dr. Bert Vogelstein, Johns Hopkins School of Medicine  
Dr. Huda Zoghbi, Baylor College of Medicine 

Sponsored by Oracle Health Sciences.

- 12:05: Presentation of the Pershing Square Sohn Prize for Young Investigators in cancer research in New York City
Chair:  Dr. Marc Tessier-Lavigne

-12:45 - 1:50:  Affordable Care Act. US Healthcare in Transition: The Stakes for Industry
Chair:  Dr. P. Roy Vagelos
Ken Frazier, Chairman, CEO and President, Merck & Co., Inc.
Alex Gorsky, Chairman and CEO, Johnson&Johnson
John Lechleiter, Chairman and CEO, Eli Lilly & Company

-1:50 - 2:55:  Neurodegenerative Disease Drug Progress 
Chair:  Dr. Marc Tessier-Lavigne, President, The Rockefeller University, New York, Professor Laboratory of Brain Development and Repair
Dr. Samantha Budd, Vice President, Neuroscience iMed at AstraZeneca R&D.
Dr. David Holtzman,  Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center . Washington University.
Dr. Morgan Sheng, Vice President, Neuroscience, Genentech Inc.
Dr. Reisa Sperling , Professor of Neurology at Harvard Medical School Department of Neurology, Brigham and Women's Hospital.

Sponsored by Alexandria Real Estate

-2:55 - 4:00:  Oncology: Newer Therapies: 
Chair:  Dr. Paul A. Marks, Laboratory Head of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, President, Emeritus, MSKCC
Herve Hoppenot, President, Novartis Oncology. Novartis Pharmaceuticals Corporation
Dr. Carl H. June, Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania
Mark Kris, Chief, Thoracic Oncology Services, Memorial Sloan-Kettering Cancer Center
Dr. Ira Mellman, Vice-President, Research Oncology, Genentech


Registration to the 4th Galien Forum

See the 2012 3rd Galien Forum Program